{
    "organizations": [],
    "uuid": "2461e5c957808522ef79daea22e9907af38a43de",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-myokardia-says-phase-3-explorer-hc/brief-myokardia-says-phase-3-explorer-hcm-study-evaluating-mavacamten-to-initiate-in-q2-2018-idUSFWN1SS0FH",
    "ord_in_thread": 0,
    "title": "BRIEF-MyoKardia Says Phase 3 Explorer-Hcm Study Evaluating Mavacamten To Initiate In Q2 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - MyoKardia Inc:\n* MYOKARDIA ANNOUNCES DESIGN OF PHASE 3 EXPLORER-HCM STUDY EVALUATING MAVACAMTEN IN SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY\n* MYOKARDIA INC - PHASE 3 EXPLORER-HCM STUDY EXPECTED TO INITIATE IN Q2 2018, TOPLINE DATA ANTICIPATED IN SECOND HALF 2020 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T19:53:00.000+03:00",
    "crawled": "2018-05-22T19:34:02.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "myokardia",
        "inc",
        "myokardia",
        "announces",
        "design",
        "phase",
        "study",
        "evaluating",
        "mavacamten",
        "symptomatic",
        "obstructive",
        "hypertrophic",
        "cardiomyopathy",
        "myokardia",
        "inc",
        "phase",
        "study",
        "expected",
        "initiate",
        "q2",
        "topline",
        "data",
        "anticipated",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}